Search
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at ser...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown eff...
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIsavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the br...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 Inducers